Life Sciences Tools and Services

Danaher

Resona Asset Management Reduces Danaher Stake; Danaher Beats Earnings Expectations but Analysts Lower Price Target

Northwest Mutual Wealth Management Increases Danaher Stake by 303.7%

RBC Resumes Coverage of Danaher, Maintains Outperform Rating with $200 Price Target

Maximo Medical Shareholders Approve Danaher Acquisition

Strs Ohio Reduces Stake in Danaher Corp.

Denmark Life Insurance Increases Stake in Danaher in Q4

Danaher Issued 3 Billion Euro Senior Notes to Finance Maximo Medical Acquisition

Danaher Plans Acquisition of Masimo, Lawsuits Prompt Additional Disclosures

Danaher stock hits 52-week low

Danaher Prices €3 Billion Euro-Denominated Senior Notes Offering

Danaher released FY2026 Q1 earnings on April 21 Pre-Market EST, actual revenue USD 5.951 B (forecast USD 5.993 B), actual EPS USD 1.45 (forecast USD 1.42)

Danaher Reports Q1 Earnings Beat

Danaher Announces Q1 Earnings with Core Sales Growth of 0.5%

Danaher Expected to Report 4.5% Q1 Revenue Growth

Danaher Sets Up New Unsecured Credit Facility to Support Commercial Paper Program

Danaher Closes $5 Billion 364-Day Revolving Credit Facility

Danaher to release FY2026 Q1 earnings on April 21 Pre-Market EST, forecast revenue USD 5.999 B, EPS USD 1.4285

Danaher Announces 2025 Fiscal Year Annual Report

Capital International Ltd. Reduced Holdings in Danaher Corporation

Danaher Corp EVP Disposes of Common Stock

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Danaher Corporation (DHR.US) Q3 2025 Earnings Call

Danaher Corporation (DHR.US) Q2 2025 Earnings Call

Danaher Corporation (DHR.US) Q4 2024 Earnings Call

Danaher Corporation (DHR.US) 2024 Third Quarter Earnings Call

SBIO

LABU

Danaher Corp. (DHR) shares rose 1.94% to $167.04 on a challenging trading day for the market, outperforming competitors like Thermo Fisher, Abbott, and Medtronic. The stock is still 31.20% below its 52-week high of $242.80. Trading volume reached 5.7 million, surpassing the 50-day average of 4.6 million.

MarketWatch Automated

iShares US Medical Devices

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Health Equip

ALPS Medical Breakthrough

iShares Biotechnology ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

S&P 500

Dow Jones Industrial Average

Thermo Fisher Scentific

Abbott Laboratories

Medtronic

Danaher Corp. Stock Outperforms Competitors On Strong Trading Day

Resona Asset Management Co. Ltd. reduced its stake in Danaher Corporation (NYSE:DHR) by 12.7% in Q4, now holding 448,050 shares valued at approximately $102.77 million. Other institutional investors have also adjusted their positions. Analysts have lowered price targets for Danaher, with a consensus rating of 'Moderate Buy' and a price target of $238.65. Danaher reported a quarterly EPS of $2.06, exceeding estimates, and announced a quarterly dividend of $0.40.

Market Beat

Goldman Sachs

Wells Fargo

Johnson Controls

GS Hldg R

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR

Northwestern Mutual Wealth Management Co. increased its holdings in Danaher Corporation (NYSE:DHR) by 303.7% in Q4, acquiring 186,584 shares, bringing total ownership to 248,020 shares valued at $56.8 million. Other institutional investors also raised their stakes. Analysts have mixed ratings on DHR, with target prices ranging from $230 to $270. Danaher reported a Q1 EPS of $2.06, exceeding estimates, with a market cap of $114.62 billion.

Enterprise Financial

Barclays

Jefferies Financial

Evercore

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Northwestern Mutual Wealth Management Co. Acquires 186,584 Shares of Danaher Corporation $DHR

Danaher (DHR) shares have dropped 5.4% in the past week and 16.9% over the last year, raising questions about its valuation. A Discounted Cash Flow analysis suggests the stock is undervalued by 28.7%, with an intrinsic value of $227.08 per share compared to its current price of $161.91. However, its P/E ratio of 31.18x indicates it may be overvalued relative to industry peers. Investors are encouraged to reassess Danaher's value amidst fluctuating market conditions.

Simplywall

Direxion S&P Biotech Bear 3X

Is It Time To Reconsider Danaher (DHR) After The Recent Share Price Slump

RBC Capital Markets projects Danaher (DHR) could achieve 6% revenue growth in 2027, driven by a rebound in bioprocess demand and improving markets. The firm notes strong demand for bioprocess consumables and equipment. Danaher is also addressing gaps in its Beckman Coulter business and expects growth from its Masimo acquisition. RBC resumed coverage with an outperform rating and a $200 price target, despite a 1.1% drop in shares to $162.75.

fidelity

ROYAL BANK OF CANADA

Masimo

Danaher Seen on Path to Growth Reacceleration on Bioprocess Recovery, RBC Says

Danaher Stock: Analyst Estimates & Ratings

Barchart Option

Danaher Stock: Analyst Estimates & Ratings

Cepheid Receives CE Marking Under IVDR for Xpert® GI Panel | CPHD Stock News

StockTitan

Cepheid Receives CE Marking Under IVDR for Xpert® GI Panel | CPHD Stock News

6869

SSMXY

The Hematology Analyzers and Reagents Market is projected to grow from USD 7.57 billion in 2026 to USD 10.33 billion by 2031, at a CAGR of 6.4%. The Asia Pacific region is expected to witness the highest growth rate, driven by increasing demand for advanced diagnostic tools and rising prevalence of blood-related diseases. The blood cancer segment is anticipated to dominate the market, accounting for 34% of revenue share in 2025. Key players include Sysmex Corporation, Danaher Corporation, and Siemens Healthineers.

prnewswire

Sysmex Corporation

Sysmex

Siemens Healthineers AG

10:15 ETHematology Analyzers and Reagents Market worth $10.33 billion by 2031 | MarketsandMarkets™

Danaher Corp. (DHR) shares fell 2.71% to $166.52 on Monday, marking its second consecutive day of losses, while the S&P 500 and Dow Jones both rose 0.19%. The stock is now 31.42% below its 52-week high of $242.80. In comparison, competitors like Thermo Fisher Scientific, Abbott Laboratories, and Medtronic also experienced declines. Trading volume reached 7.0 million, surpassing the 50-day average of 4.4 million.

Danaher Corp. Stock Underperforms Monday When Compared To Competitors

Danaher(DHR.US)

Danaher Corp. Stock Outperforms Competitors On Strong Trading Day

Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR

Northwestern Mutual Wealth Management Co. Acquires 186,584 Shares of Danaher Corporation $DHR

Is It Time To Reconsider Danaher (DHR) After The Recent Share Price Slump

Danaher Seen on Path to Growth Reacceleration on Bioprocess Recovery, RBC Says

Danaher Stock: Analyst Estimates & Ratings

Cepheid Receives CE Marking Under IVDR for Xpert® GI Panel | CPHD Stock News

10:15 ETHematology Analyzers and Reagents Market worth $10.33 billion by 2031 | MarketsandMarkets™

Danaher Corp. Stock Underperforms Monday When Compared To Competitors